Pfizer – Wyeth Acquisition Abstract The board of Pfizer, the world’s largest drug maker, has agreed to acquire a long-time rival, Wyeth, for $68 billion. The Pfizer-Wyeth merger will create a prescription pharmaceutical company of extraordinary scale. Despite long-term patent and marketing challenges, most industry observers believe Pfizer has little choice but to engage in some type of major acquisition, especially given the recent loss of income on Lipitor. Pfizer needs to reassure its
Words: 604 - Pages: 3
Combinations – ACC 638 (T, 6:55pm-9:20pm) 11 May 2011 Pfizer & Wyeth When Pfizer announced an agreement to buy Wyeth in January 2009, it was expected to not only create a pharmaceutical behemoth which would be the biggest merger since AT&T and BellSouth in March 2006 (according to the research firm Capital IQ but also would be an extraordinary event in such a financial crisis for the period 2008-2009 because this was not a desperate merger of two financial institutions orchestrated by the government
Words: 1243 - Pages: 5
Executive Summary: Pfizer-Wyeth Merger Deal Overview: On January 25, 2009, Pfizer and Wyeth entered into the merger agreement, pursuant to which, subject to the terms and conditions set forth in the merger agreement, Wyeth will become a wholly-owned subsidiary of Pfizer. Upon completion of the merger, each share of Wyeth common stock issued and outstanding will be converted into the right to receive, subject to adjustment under limited circumstances, a combination of $33.00 in cash, without interest
Words: 8308 - Pages: 34
Case 25: Pfizer Porsha Erwin Angel Harvey Curtis Hubbard DeMontrez Johnson Michael Kitchens China Thomas 1 Table of Contents History……………………………………………………………………………..Page 3 Summary…………………………………………………………………………..Page 3 General Environment Analysis……………………………..……………………Page 5 Industry Environment Analysis………………………………………………….Page 6 EFE Matrix………………………………………………………………………..Page 9 Internal Competencies …………………………………………………………...Page 10 IFE Matrix………………………………………………………………………...Page 12
Words: 2443 - Pages: 10
Course Project: Pfizer Inc. Fall 2010, F203A: Financial Accounting for Management Group 8 Heejun Chung Serge Sidorov Tim Harvey Brett Neu Ed Wu 1. Table of Figures Exhibit 1 in the Appendix contains a table of figures that is comprised of data pertinent to Pfizer’s financial performance in 2007 – 2009. 2. Common Size Balance Sheet Analysis a. Common size balance sheets for Pfizer and Novartis in 2007 – 2009 are shown in Appendix (Exhibit 2). b
Words: 2136 - Pages: 9
requires a strategic manager who can effectively and successfully drive strategic objectives, then report its performance to the leadership team (Thompson & Strickland, 2013). This paper will examine how Pfizer utilized growth, innovation and execution strategies as well as acquisitions and mergers to become the number one global pharmaceutical company. The organization’s SWOT analysis (Thompson & Strickland, 2013) showed its strength in being innovative, opportunities to create more products, weakness
Words: 4579 - Pages: 19
pratiwi kadarno tirto 1701361951/LF53 Motivation for pzifer’s acquisition of Wyeth Pada Januari 2009, perusahaan farmasi terbesar di dunia Pfizer mengumumkan bahwa perusahaan tersebut akan mengakuisisi Wyeth, yang juga merupakan perusahaan farmasi yang besar, dimana nilai akuisisi tersebut mencapai $68 Milyar dalam bentuk saham dan tunai. CEO dari Pfizer Jeffery Kindler berkata bahwa kombinasi dari Pfizer dan Wyeth akan memberikan kesempatan yang besar untuk mentransformasi industry
Words: 480 - Pages: 2
FINANCIAL ANALYSIS OF WYETH PAKISTAN LIMITED By: OZAIR ARSHAD INDEX 1. Introduction 2. History and Profile 3. Key Activities of Wyeth 4. Wyeth Products Profile 5. Data Collection & Market Assessment 6. Main Competitors 7. Share Price in Last 12 Months 8. Shareholding Pattern 9. The Director’s Report 10.The Auditor’s Report 11.Financial Ratios & Analysis 12. Horizontal Analysis a) Income Statement b)Balance Sheet 13. Vertical Analysis a)Balance Sheet b) Income Statement 14. Financial Analysis
Words: 4036 - Pages: 17
have inadvertently empowered hedge funds that push for short-term solutions” (LaMattina, 2012). Mergers have taken place over the last 10 years (Pfizer-Wyeth) and can have great short term payouts, they bring a reduction in redundancies and greater cash flow. However they can have disastrous outcomes, especially to research and development sections that are especially susceptible to disruptions like a merger. Over the last decade, budgets for R&D have been decreasing because these big pharma companies
Words: 334 - Pages: 2
The Pharmaceutical industry in the Global Economy Summer 2005 Larry Davidson* and Gennadiy Greblov Indiana University Kelley School of Business Bloomington, Indiana *Davidson is Professor of Business Economics and Public Policy and Greblov is working towards his MBA degree at the Kelley School of Business Prepared for the Indiana Economic Development Corporation with the support of the Center for International Business Education and Research at the Indiana
Words: 10094 - Pages: 41
